• en
ON NOW

WHO Approves Emergency Use of China’s Sinopharm Covid Vaccine

The World Health Organization has approved the emergency use of a Covid-19 vaccine manufactured by China’s Sinopharm. Friday’s decision by a WHO technical advisory group, a first for a Chinese

Morgantown, WV – 16 December 2020: Small bottle of coronavirus vaccine with syringe with background of the Chinese company Sinopharm logo

The World Health Organization has approved the emergency use of a Covid-19 vaccine manufactured by China’s Sinopharm.

Friday’s decision by a WHO technical advisory group, a first for a Chinese vaccine, opens the possibility that Sinopharm’s offering could be included in the United Nations-backed COVAX programme in coming weeks or months, and distributed through United Nations children’s agency UNICEF and WHO’s Americas regional office.

Aside from efficacy numbers, the Chinese manufacturer has released very little public data about its two vaccines – one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.

The Beijing-made Sinopharm shot is one the WHO advisory group considered for the emergency use listing.

“This afternoon, WHO gave emergency use listing to sign off on Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality,” WHO Director-General Tedros Adhahom Ghebreyesus said.

The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorisation from the UN health agency.

“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.

Sinopharm has not published its late-stage test results in scientific journals, so the WHO requested a breakdown of its data, which come mostly from the United Arab Emirates.

A summary posted online by WHO suggests the vaccine is about 78 percent effective, with the caveat that all but a few hundred of the study volunteers were younger than 60.

Gavi, the Vaccine Alliance, which co-runs COVAX, welcomed WHO’s approval of emergency use.

“This means the world has yet another safe and effective tool in the fight against this pandemic,” the alliance said.

ON NOW